REperfusion Therapy for Acute Ischemic STrOke Due to Large aRtEry Occlusion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-23

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study was to establish a clinical and advanced imaging database of acute ischemic stroke patients treated with mechanical thrombectomy due to large vessel occlusion of anterior circulation within 24 hours from stroke onset in China, and to investigate the predictors and potential mechanisms of futile recanalization after mechanical thrombectomy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Registry of Acute Ischemic Stroke With Large- or Medium-vessel Occlusion

NCT05779215

Acute Ischemic Stroke

RECRUITING

Head-down Position for Acute Ischemic Stroke With Large Artery Atherosclerosis

NCT03744533

Ischemic Stroke

COMPLETED NA

A Retrospective Study of Reco Thrombectomy Stent for Intravascular Treatment of Acute Ischemic Stroke

NCT05166733

Neurology Interventional Therapy

UNKNOWN

Prospective Registry Study of Endovascular Treatment for Acute Ischemic Stroke Patients

NCT05988125

Endovascular Treatment

RECRUITING

Endovascular Treatment Key Technique and Emergency Work Flow Improvement of Acute Ischemic Stroke

NCT03370939

Intracranial Artery Occlusion With Infarction (Disorder)

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The time-window of mechanical thrombectomy for ischemic stroke has extended from 4.5 hours to 24 hours based on the results of the DAWN and DEFUSE 3 trials. However, evidence on the effectiveness and safety of mechanical thrombectomy within 24 hours in the real-world is insufficient.

This is a multi-center, prospective, registry cohort study that acute ischemic stroke patients treated with mechanical thrombectomy due to large vessel occlusion of anterior circulation within 24 hours from stroke onset in China. A retrospective dataset was also build in these stroke centers for analysis. A total of 1600 patients with advanced imaging data were anticipated to be enrolled.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Vascular Occlusion Endovascular Treatment Mechanical Thrombectomy Perfusion Imaging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Older than 18 years;
* Perfusion imaging completed including CTA+CTP or MRA+PWI+DWI before thrombectomy
* Large vessel occlusion of cerebral anterior circulation (ICA, MCA-M1 or MCA-M2) confirmed by CTA or MRA, planned to receive or received stenting or aspiration thrombectomy
* Time intervals ≤ 24 hours from stroke onset to groin puncture.(fulfilled the inclusion of DAWN or DEFUSE 3 trial if the time intervals from stroke onset to groin puncture was ≥6 hours)
* mRS score ≤2 before admission
* Informed consent obtained for longitudinal enrolled patients, waived of consent for retrospectively included cases

Exclusion Criteria

* Had a history of infective disease, immunity disease, radiotherapy at head or neck, carotid dissection or other carotid disease.
* Unable to receive CT or MR scan due to heart failure, cardiac pacemaker, metal implants or claustrophobia, etc.
* Unable to be injected with contrast agent due to allergy, renal dysfunction, etc.
* Unlikely to adhere to the study protocol or follow-up ( life expectancy ≤ 3 months)
* Already participated in other drug trials

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No